In addition, the acquired findings were used to develop a novel model for testing HSD10 inhibitors, enabling the scoring of their ability to reduce pathology linked to HSD10 and Aβ, two critical factors in AD progression. This evidence concerns the gene FSIP1 and Alzheimer disease.